The estimated Net Worth of Claudia De Oliveira Ribeiro... is at least 1.79 百万$ dollars as of 15 January 2015. Claudia Ribeiro owns over 2,396 units of PTC Therapeutics Inc stock worth over 1,335,849$ and over the last 11 years Claudia sold PTCT stock worth over 453,625$.
Claudia has made over 8 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Claudia exercised 2,396 units of PTCT stock worth 25,997$ on 15 January 2015.
The largest trade Claudia's ever made was exercising 49,478 units of PTC Therapeutics Inc stock on 10 October 2014 worth over 536,836$. On average, Claudia trades about 8,137 units every 33 days since 2014. As of 15 January 2015 Claudia still owns at least 41,396 units of PTC Therapeutics Inc stock.
You can see the complete history of Claudia Ribeiro stock trades at the bottom of the page.
Claudia's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC.,, 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over 50,602,930$ worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth 57,374,337$ . The most active insiders traders include Suisse/ Credit、Adam Koppel、Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of 888,748$. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth 77,191$.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: